Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation

Abstract Background Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D122...

Full description

Bibliographic Details
Main Authors: Toshio Fujino, Kenichi Suda, Takamasa Koga, Akira Hamada, Shuta Ohara, Masato Chiba, Masaki Shimoji, Toshiki Takemoto, Junichi Soh, Tetsuya Mitsudomi
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Journal of Hematology & Oncology
Online Access:https://doi.org/10.1186/s13045-022-01299-z

Internet

https://doi.org/10.1186/s13045-022-01299-z

Similar Items